Crest

Parkinson's disease patients at the end of life often do not receive optimal care due to challenges specific to the disease that non-specialists may not fully understand. Research at CHU Rennes from 2006 to 2018 revealed that many patients stopped antiparkinsonian treatments before death without specialist guidance, leading to a distressing dopaminergic withdrawal syndrome. Additionally, Parkinson's patients rarely pass away in hospitals, and in France, many are cared for at home through palliative or intensive nursing efforts, highlighting the need for specialized local clinical and pharmacological care. This trial evaluates the use of a continuous subcutaneous apomorphine pump for Parkinson's patients receiving home hospitalization for palliative care who have advanced disease and have discontinued oral treatments. The pump is provided as part of routine care, and patient comfort and symptoms are monitored using a series of questionnaires at multiple time points from day 0 through day 45. These include assessments of stiffness, pain, sedation/agitation, and caregiver experiences. Participants will complete or have completed various clinical questionnaires at nine scheduled visits over 45 days to assess motor and non-motor symptoms, patient comfort, and caregiver burden. The primary outcome focuses on measuring rigidity at the start and on day 6. The study aims to provide insights into how this treatment affects symptom management and quality of life in the final stages of Parkinson's disease while involving multidisciplinary teams experienced in both palliative and Parkinson's care.